

## 340B Notice Regarding Updated Limited Distribution Plan for Nulojix (belatacept)

September 12, 2019

This notice provides information for 340B covered entities regarding the distribution of Nulojix (belatacept) NDC#00003037113. Nulojix is an orphan drug therapy. Specifically, Nulojix is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. Nulojix is administered through an intravenous infusion, and it is used with corticosteroids and certain other medicines.

This notice is an update to our previous communication on necessary limited distribution plan for Nulojix. In the prior notice, dated February 21, 2017, Bristol-Myers Squibb (“BMS”) communicated that the supply of Nulojix in 2017 would not be sufficient to enable new patients to start treatment with Nulojix. In order to ensure that the existing patients being treated with Nulojix continue to have access to this medicine, BMS has developed a limited distribution plan to achieve this goal. All pharmacies - 340B and otherwise – are subject to this plan equally. BMS is providing a service to ensure continued access to Nulojix for all existing patients through the Nulojix Distribution Program. BMS wants to notify covered entities that our supply of Nulojix and the Nulojix Distribution Program will allow **new** patients to have access to Nulojix as well.

- You still must register your existing patients in the Nulojix Distribution Program and receive a unique patient identification number. You now may register new patients as well.
- **A unique patient identification number will be required when placing orders for Nulojix.** A unique patient identification number can be obtained by completing a registration form. Please call 1-855-511-6180 to request a registration form. Once registered, you will receive notification of enrollment.
- **McKesson Plasma and Biologics will be the exclusive distributor of Nulojix in support of the Nulojix Distribution Program.** Please contact McKesson Plasma and Biologics directly at 1-877-625-2566 to confirm your existing account and/or establish a purchasing relationship.

Once the Nulojix Distribution Program registration form is complete and faxed to the program, you will be notified whether the patient was successfully registered into the program. Acceptance is premised purely on supply; no other criteria will be used in reviewing the form other than completion.

BMS takes its obligations under the 340B program seriously and will make every effort to ensure that Nulojix is available to 340B covered entities in a manner that is no more restrictive than it is for non-340B entities. If you have any questions regarding this program, please call the Nulojix Distribution Program at 1-855-511-6180 from 8AM to 8PM ET, Monday through Friday (except holidays).